Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in advanced solid tumors
NCT02628067Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2015
- Primary completion
- May 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of pembrolizumab in anal squamous cell carcinoma (SCCA), biliary adenocarcinoma, cholangiocarcinoma (CCA), Neuroendocrine Neoplasm (NEN), endometrial carcinoma, sponsored by Merck & Co.. Started Dec 2015; status: active, not recruiting.
02
Drugs
03
Conditions
anal squamous cell carcinoma (SCCA)biliary adenocarcinomacholangiocarcinoma (CCA)Neuroendocrine Neoplasm (NEN)endometrial carcinoma
Beyond the preview
Go deeper on NCT02628067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02628067.